Teleflex Incorporated

NYSE:TFX Voorraadrapport

Marktkapitalisatie: US$5.6b

Teleflex Toekomstige groei

Future criteriumcontroles 3/6

Teleflex zal naar verwachting groeien in winst en omzet met respectievelijk 71.2% en 4.1% per jaar. De winst per aandeel zal naar verwachting groeien met 76.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 16.1% zijn.

Belangrijke informatie

71.2%

Groei van de winst

76.55%

Groei van de winst per aandeel

Medical Equipment winstgroei17.0%
Inkomstengroei4.1%
Toekomstig rendement op eigen vermogen16.06%
Dekking van analisten

Good

Laatst bijgewerkt25 Aug 2026

Recente toekomstige groei-updates

Recent updates

Narratiefupdate • Sep 03

TFX: Margin Expansion And Capital Deployment Will Guide Balanced Execution Outlook

Teleflex's analyst fair value estimate has been lifted by about $5 to $153.55 as analysts factor in recent Q2 earnings updates, continuing price target increases across the Street, and a stronger margin outlook despite more cautious revenue assumptions. Analyst Commentary Recent Street research around Teleflex points to a mixed but generally constructive tone, with several firms lifting price targets following Q2 results and company updates.
Seeking Alpha • Aug 23

Teleflex: Portfolio Surgery Creates A Better Medtech Compounder

Summary Teleflex is transforming into a focused procedural technology platform, divesting lower-growth units and reinvesting in high-acuity Vascular and Surgical segments. TFX's Vascular and Surgical segments are generating high-single-digit growth, while Interventional segment weakness is attributed to temporary integration challenges. Proceeds from divestitures are funding debt reduction and substantial share repurchases, enhancing per-share earnings potential and financial flexibility. I expect margin recovery and valuation upside by 2027, contingent on successful integration, cost savings, and renewed Interventional segment growth. Read the full article on Seeking Alpha
Narratiefupdate • Aug 15

TFX: Biotronik Synergies And Portfolio Separation Will Drive 2027 Earnings Inflection

Analysts have lifted the Teleflex fair value estimate to $169 from $160, reflecting updated models after Q2 earnings, a focus on margin expansion, and reassessment of future P/E assumptions and revenue contributions from Biotronik and capital deployment. Analyst Commentary Recent Street research on Teleflex points to a generally constructive tone following Q2 results, with many bullish analysts lifting price targets and highlighting specific growth and margin drivers.
Narratiefupdate • Jul 31

TFX: Product Approvals And Capital Deployment Plans Will Shape Balanced Forward Outlook

Analysts have nudged their price expectations for Teleflex higher, with the fair value estimate moving from $143.67 to $148.55. They cite recent price target increases linked to new product approvals, capital deployment plans and a range of fresh coverage initiations.
Narratiefupdate • Jul 07

TFX: Biotronik Synergies And Portfolio Separation Will Reshape Earnings Profile

Analysts have lifted their fair value estimate for Teleflex stock from $155 to $160 as they factor in potential benefits from Biotronik-related synergies, capital deployment that is still filtering into Street models, and possible value creation linked to activist involvement. Analyst Commentary Recent research updates around Teleflex highlight a more constructive tone from bullish analysts, with several price target revisions and rating changes aligning around the new US$160 fair value estimate.
Narratiefupdate • Jun 22

TFX: Biotronik Synergies And Activist Pressure Will Shape Execution Risk Going Forward

Analysts have raised the fair value estimate for Teleflex stock from $116.81 to $135.00, reflecting updated assumptions around capital deployment, Biotronik-related synergies, potential activist-driven value creation, and a slightly higher future P/E multiple. Analyst Commentary Recent Street research on Teleflex has focused on how potential Biotronik synergies, capital deployment plans, and possible activist involvement could influence the stock's risk and reward profile.
Analyse-artikel • Jun 19

Teleflex (TFX) Stock Could Be 11.6% Undervalued After Q1 Revenue Beat

Teleflex stock reaction centered on earnings, not new debt issue Teleflex (TFX) has been drawing attention after Q1 revenue topped analyst expectations and investors responded positively, even as the company issued new senior notes and reiterated full year EPS guidance below prior estimates. The recent share price move appears more closely linked to Teleflex's earnings update, where revenue performance and progress on its transformation plan supported sentiment, rather than to the sizeable...
Narratiefupdate • Jun 06

TFX: Portfolio Reset And Recent Upgrades Will Shape Balanced Forward Outlook

Analysts have raised their fair value estimate for Teleflex from $129.25 to about $143.67, citing a lower required discount rate, an updated view on revenue growth and margins, and a higher assumed future P/E multiple following several recent upgrades and target increases from major firms. Analyst Commentary Recent Street research on Teleflex has leaned constructive, with several firms updating ratings and price targets in quick succession.
Narratiefupdate • May 23

TFX: Business Separation And Portfolio Shift Will Drive Future Earnings Repricing

Narrative Update on Teleflex The updated analyst price target for Teleflex moves to $155 from $147, with analysts citing recent upgrades and price target increases, along with the company's ongoing business separation and portfolio optimization efforts, as key supports for the higher fair value and slightly adjusted discount rate and P/E assumptions. Analyst Commentary Recent street research around Teleflex has leaned positive, with several bullish analysts updating views in quick succession.
Narratiefupdate • May 02

TFX: Business Separation And Portfolio Focus Will Reshape Future Earnings Profile

Analysts have reduced their fair value estimate for Teleflex to $147 from $155, citing updated assumptions for revenue growth, profit margins, and future P/E multiples following recent upgrades and price target increases from several research firms. Analyst Commentary Recent research has skewed more optimistic on Teleflex, with several bullish analysts updating their views following the company’s Q4 results, guidance, and plans for a major business transformation.
Narratiefupdate • Apr 17

TFX: Business Separation Execution And Activist Pressure Will Constrain Forward Upside

Teleflex's analyst price target is now framed slightly higher, moving from about $115 to roughly $117. Analysts are factoring in updated assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E following recent upgrades and price target increases tied to the company's ongoing business separation and portfolio optimization efforts.
Narratiefupdate • Apr 03

TFX: Business Separation And Activist Pressure Will Shape Balanced Forward Outlook

Analysts have raised their average price target for Teleflex to $125 from $115. They cite the company’s ongoing business separation, portfolio optimization, and preparation for future value-creating opportunities as key reasons for the change.
Narratiefupdate • Mar 20

TFX: Business Separation And Leadership Changes Will Shape Balanced Forward Outlook

Narrative update Analysts have raised the Teleflex price target by $10, to $125 from $115, citing the company's business separation efforts, portfolio optimization, and positioning for future value creating opportunities following recent results and guidance. Analyst Commentary Recent research highlights a mixed backdrop for Teleflex, with some firms adjusting targets higher while others stay guarded.
Narratiefupdate • Mar 06

TFX: Business Separation And Portfolio Optimization Will Drive Future Earnings Quality

Narrative Update on Teleflex The analyst price target on Teleflex has shifted toward $125, with analysts pointing to the company’s ongoing business separation, portfolio optimization, and positioning for future value-creating opportunities as key factors behind the revised outlook. Analyst Commentary Bullish analysts are pointing to recent price target moves and rating actions as signals of growing confidence in Teleflex’s ability to execute on its transformation plan and to support higher valuation levels over time.
Narratiefupdate • Feb 20

TFX: Higher Margin Assumptions And CEO Transition Will Shape Bullish Outlook

Narrative Update on Teleflex The updated analyst price target on Teleflex has shifted by $23, with analysts citing refreshed views on long term profit margins and a slightly higher assumed future P/E multiple as key drivers behind the change. Analyst Commentary Recent Street research on Teleflex reflects a mix of optimism about the company’s long term potential and caution around valuation and execution, which helps explain the updated price target.
Narratiefupdate • Feb 06

TFX: CEO Transition And Refined Assumptions Will Shape Bullish Future Outlook

Analysts have adjusted their price targets on Teleflex by aligning fair value estimates to about $129.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions highlighted in recent research, including a Wells Fargo target cut and a Needham upgrade.
Narratiefupdate • Jan 23

TFX: Leadership Transition And Softer Demand Will Shape Steady Forward Outlook

Analysts kept their Teleflex fair value estimate steady at US$115.00, as slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E led them to view the prior price target as still appropriate. What's in the News Board member Stuart Randle has been appointed Interim President and CEO effective January 8, 2026, replacing Liam Kelly.
Narratiefupdate • Jan 09

TFX: Softer Demand And Leadership Change Will Shape Balanced Outlook

Analysts have reduced their price target on Teleflex from US$120.00 to US$115.00, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News Teleflex issued preliminary 2025 revenue guidance of US$3.270b to US$3.278b, below its prior outlook of US$3.305b to US$3.320b, citing softer demand for intra aortic balloon pumps and catheters in the U.S. and Asia, delays in OEM purchase orders, and lower order volumes across parts of its portfolio (Key Developments).
Narratiefupdate • Dec 20

TFX: Margin Expansion Will Drive Stronger Earnings Despite Revenue Headwinds

Analysts have raised their price target on Teleflex from 152.80 dollars to 155.00 dollars, reflecting expectations for meaningfully higher profit margins that more than offset slightly slower projected revenue growth and a lower future earnings multiple. What's in the News Teleflex narrowed its full year 2025 GAAP revenue growth outlook to 9.10% to 9.60%, and now expects revenue between 3,325 million dollars and 3,340 million dollars.
Narratiefupdate • Dec 06

TFX: Diabetes Trial And Goodwill Charge Will Shape Balanced Future Outlook

Analysts have modestly adjusted their price target on Teleflex, keeping fair value steady at approximately $124.14 per share while refining assumptions for a slightly lower discount rate and marginally improved long term valuation metrics. This reflects incremental confidence in the company’s earnings durability.
Narratiefupdate • Nov 22

TFX: Future Diabetes Trial Progress Will Drive Upside Despite Margin Pressures

Teleflex's analyst price target has been revised downward by $3.57 to $124.14. Analysts cite modest reductions in expected profit margins and growth as driving factors for the update.
Analyse-artikel • Nov 09

Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34

Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...
Narratiefupdate • Nov 07

TFX: Future Advances In Diabetes Trials And Asian Market Expansion Will Drive Upside

Analysts have revised their price target for Teleflex downward from $132.63 to $127.71. They cite higher discount rates and softer revenue growth projections, despite improved profit margins and a lower expected future price-to-earnings ratio.
Analyse-artikel • Oct 30

Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing

Teleflex Incorporated's ( NYSE:TFX ) price-to-earnings (or "P/E") ratio of 29.5x might make it look like a strong sell...
Narratiefupdate • Aug 29

Acquisitions And Asian Expansion Will Broaden Healthcare Horizons

Despite a near-term upside from strong Q2 results, Teleflex’s consensus price target has been revised down to $132.62 due to persistently modest organic growth and muted EPS increases, with valuation already reflecting current expectations despite anticipated second-half acceleration. Analyst Commentary Strong Q2 results provided near-term upside surprise.
Seeking Alpha • Mar 02

Teleflex's Bold Transformation: Why I'm Skeptical On Value Creation

Summary Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak revenue growth and margin leverage, with potential risks from tariffs and poor execution in key areas. The acquisition of BIOTRONIK's vascular intervention business is risky; it expands Teleflex's vascular intervention business, but the end markets aren't growing that fast and the company is a smaller player. Splitting the business into RemainCo and NewCo makes strategic sense, but NewCo may struggle with growth and margin leverage as a smaller entity. Even with conservative modeling and valuation assumptions, Teleflex stock looks undervalued by more than 20%, but it's tough to recommend a stock where I have serious doubts about execution and strategy. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NYSE:TFX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20282,4772673632929
12/31/20272,36717140636313
12/31/20262,26812111426213
6/30/20262,255-25327403N/A
3/31/20262,1271227317N/A
12/31/20251,99359245341N/A
9/28/20251,217-438313391N/A
6/29/20251,06982445514N/A
3/30/20251,37694522598N/A
12/31/20241,70057545636N/A
9/29/20243,026238450572N/A
6/30/20243,008265417543N/A
3/31/20243,001296430538N/A
12/31/20231,712144464511N/A
10/1/20232,959405381471N/A
7/2/20232,899369326412N/A
4/2/20232,860363278366N/A
12/31/20222,791363264344N/A
9/25/20222,795412373445N/A
6/26/20222,808510421488N/A
3/27/20222,817488537603N/A
12/31/20212,810485580651N/A
9/26/20212,759434565645N/A
6/27/20212,687351479567N/A
3/28/20212,540280468559N/A
12/31/20202,537336346436N/A
9/27/20202,507367307389N/A
6/28/20202,527479N/A413N/A
3/29/20202,612551N/A364N/A
12/31/20192,595462N/A440N/A
9/29/20192,556442N/A427N/A
6/30/20192,517269N/A416N/A
3/31/20192,475183N/A415N/A
12/31/20182,448196N/A437N/A
9/30/20182,40266N/A404N/A
7/1/20182,32789N/A404N/A
4/1/20182,246170N/A416N/A
12/31/20172,146155N/A420N/A
10/1/20172,065259N/A427N/A
7/2/20171,986246N/A425N/A
4/2/20171,931227N/A432N/A
12/31/20161,868237N/A408N/A
9/25/20161,828267N/A426N/A
6/26/20161,816262N/A373N/A
3/27/20161,795248N/A326N/A
12/31/20151,799236N/A301N/A
9/27/20151,798197N/A255N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat TFX de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 3.7% ).

Winst versus markt: Er wordt verwacht dat TFX de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat TFX binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van TFX ( 4.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 13.4% per jaar).

Hoge groei-inkomsten: De omzet van TFX ( 4.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen TFX zal naar verwachting over 3 jaar laag zijn ( 16.1 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/09/14 05:45
Aandelenkoers aan het einde van de dag2026/09/14 00:00
Inkomsten2026/06/30
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Teleflex Incorporated wordt gevolgd door 27 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Matthew TaylorBarclays
Vikramjeet ChopraBMO Capital Markets Equity Research
Travis SteedBofA Global Research